Clinical trial
A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or…
NCT00325494 · Morphotek, Industry · Completed
Key facts
| NCT number | NCT00325494 |
|---|---|
| Title | A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer |
| Official title | A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-009, a Chimeric Monoclonal Antibody, in Subjects With Advanced Mesothelin-expressing Tumors |
| Lead sponsor | Morphotek, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer, Mesothelioma, Ovarian Cancer, Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | MORAb-009 |
| Enrollment | 24 |
| Start date | May 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | May 12, 2006 |
| Last update posted | Jul 17, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: